177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
J Zang, Q Liu, H Sui, R Wang, O Jacobson… - Journal of Nuclear …, 2020 - Soc Nuclear Med
This study was designed to assess the safety and therapeutic response to 177Lu-labeled
Evans blue–modified prostate-specific membrane antigen (PSMA) 617 (EB-PSMA-617) …
Evans blue–modified prostate-specific membrane antigen (PSMA) 617 (EB-PSMA-617) …
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
A Yordanova, P Linden, S Hauser… - European journal of …, 2019 - Springer
Background Data are sparse regarding the feasibility of radioligand therapy (RLT) with [177
Lu] Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of …
Lu] Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of …
[PDF][PDF] 5.1 Outcome and safety of re-challenge [177Lu] Lu-PSMA-617 in patients with metastatic prostate cancer
AYPLS Hauser, MM Stefan, KGFFC Gaertner… - Radiometalle in der …, 2022 - d-nb.info
Background There is a sparse data regarding the feasibility of radioligand therapy (RLT)
with [177Lu] Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of …
with [177Lu] Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of …